Potential Treatment for

Lp(a) or Elevated Lipoprotein (a)

Elevated Lipoprotein (a)

The purpose of this research study is to learn more about muvalaplin (LY3473329), a possible new investigational drug for the treatment of elevated lipoprotein (a) [Lp(a)], a type of fat in your blood that is not good for your health.

Study information:

  • Condition: Elevated Lipoprotein (a) [Lp(a)]

  • Location: Albuquerque, New Mexico

  • Duration: Up to 5.25 years

  • Participation: Up to 24 visits

Eligibility:

  • Age 18 or older

  • At risk for or experienced prior atherosclerotic cardiovascular disease (ASCVD) event

  • Have elevated lipoprotein (a)

  • Other study requirements apply.

Participants may receive:

  • Regular check-ins with a team of doctors and nurses to monitor your health

  • Study drug, study treatments, and procedures that are directly related to the study at no cost

  • Access to a potential new treatment option

Get started today.

You are not committed to participate in a study by completing this form. Participation is voluntary, and you may leave at any time if you change your mind.

Why is this study important?

The study aims to learn:

  • Whether muvalaplin can reduce problems like heart attack, stroke, or the need for a procedure to restore blood flow to areas of your heart in adults with elevated lipoprotein(a)

  • Whether it works better than a placebo (a placebo is an inactive or “pretend” drug that looks like the study drug)

  • What are the possible side effects